Literature DB >> 28848105

Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites.

Jennifer Zitser1, Avner Thaler, Noit Inbar, Alona Gad, Achinoam Faust-Socher, Diana Paleacu, Marieta Anca-Herschkovitch, Yakov Balash, Hertzel Shabtai, Elissa L Ash, Ludmila Merkin, Yael Manor, Meir Kestenbaum, Aya Bar David, Chava Peretz, Tova Naiman, Anat Bar-Shira, Avi Orr-Urtreger, Nira Dangoor, Nir Giladi, Tanya Gurevich.   

Abstract

BACKGROUND: Worldwide prevalence estimates of Huntington disease (HD) vary widely, with no reliable information regarding the Jewish population in Israel.
METHODS: This specialized tertiary single-center cross-sectional study assessed clinical, cognitive, and demographic characteristics of 84 HD patients who were treated at the Movement Disorder Unit of the Tel Aviv Medical Center, Israel.
RESULTS: Our cohort was composed of one-third Ashkenazi Jews, 27% Mountain Jews (Caucasus Jews), 18% Sephardi Jews, and 21% Karaites, with both Mountain Jews and Karaites over-represented compared to their relevant proportion in the population of the state of Israel, which is less than 1%. No between-group differences were detected regarding the number of CAG (cytosine-adenine-guanine) repeats, age at onset, disease duration, years from symptom onset to diagnosis, gender, years of education, Unified Huntington Disease Rating Scale scores, or the Montreal Cognitive Assessment scores.
CONCLUSION: We detected clustering of HD among the population treated at our Medical Center, which has the only specialized HD clinic in the country, with a high percentage of HD among 2 relatively small subpopulations of Jews: Mountain Jews and Karaites.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Huntington disease; Karaites; Mountain Jews

Mesh:

Substances:

Year:  2017        PMID: 28848105     DOI: 10.1159/000479375

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  1 in total

1.  The impact of ethnicity on the clinical presentations of spinocerebellar ataxia type 3.

Authors:  Shi-Rui Gan; Karla P Figueroa; Hao-Ling Xu; Susan Perlman; George Wilmot; Christopher M Gomez; Jeremy Schmahmann; Henry Paulson; Vikram G Shakkottai; Sarah H Ying; Theresa Zesiewicz; Khalaf Bushara; Michael D Geschwind; Guangbin Xia; S H Subramony; Liana Rosenthal; Tetsuo Ashizawa; Stefan M Pulst; Ning Wang; Sheng-Han Kuo
Journal:  Parkinsonism Relat Disord       Date:  2020-02-17       Impact factor: 4.891

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.